StockNews.com started coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI – Free Report) in a report released on Thursday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
CASI Pharmaceuticals Trading Up 20.3 %
Shares of NASDAQ CASI opened at $3.61 on Thursday. CASI Pharmaceuticals has a twelve month low of $1.85 and a twelve month high of $8.48. The company has a market capitalization of $48.30 million and a price-to-earnings ratio of -1.20. The firm has a 50-day moving average of $5.21 and a two-hundred day moving average of $4.83.
Institutional Investors Weigh In On CASI Pharmaceuticals
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC acquired a new stake in CASI Pharmaceuticals in the 3rd quarter valued at about $27,000. Susquehanna International Group LLP lifted its holdings in CASI Pharmaceuticals by 70.6% in the 4th quarter. Susquehanna International Group LLP now owns 57,395 shares of the biotechnology company’s stock valued at $100,000 after acquiring an additional 23,758 shares during the last quarter. Virtu Financial LLC lifted its holdings in CASI Pharmaceuticals by 39.6% in the 1st quarter. Virtu Financial LLC now owns 112,777 shares of the biotechnology company’s stock valued at $91,000 after acquiring an additional 31,971 shares during the last quarter. Finally, Citigroup Inc. acquired a new stake in CASI Pharmaceuticals in the 1st quarter valued at about $59,000. 22.23% of the stock is owned by institutional investors and hedge funds.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.
Further Reading
- Five stocks we like better than CASI Pharmaceuticals
- Investing in Travel Stocks Benefits
- 3 Value Stocks Too Small For Buffett’s Portfolio
- What Are the U.K. Market Holidays? How to Invest and Trade
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
